サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1386505

ムコ多糖症治療市場レポート：2030年までの動向、予測、競合分析

Mucopolysaccharidosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ムコ多糖症治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年10月11日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ムコ多糖症治療の動向と予測

世界のムコ多糖症治療市場は、2024年から2030年までのCAGRが8.4%で、2030年までに推定42億米ドルに達すると予測されています。この市場の主な促進要因は、効果的な治療法に対する需要の増加、ムコ多糖症の有病率の上昇、ヘルスケア支出の増加です。世界のムコ多糖症治療市場の将来は、病院と専門クリニックの市場における機会によって有望視されています。

ムコ多糖症治療市場の洞察

Lucintelの予測では、酵素補充療法はMPS患者の症状やQOLの改善に役立ち、寿命も延ばせることから、病院や診療所からの需要が高く、引き続き大きな分野です。

この市場において、病院はMPS治療を提供するために必要な専門的な検査室や機器などのインフラ、訓練を受けた医療専門家などの専門知識を有しているため、予測期間中も最大セグメントであり続けると思われます。

北米は、確立された医療制度とMPS償還政策に支えられたMPSの高い有病率により、最大セグメントであり続けると思われます。

本レポートでは、以下の11の主要な質問について回答する：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.今後成長が加速するセグメントとその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のムコ多糖症治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のムコ多糖症治療市場の動向（2018～2023年）と予測（2024～2030年）
  • タイプ別の世界のムコ多糖症治療市場
    • MPS-I
    • MPS-Ⅱ
    • MPS-IV
    • MPS-VI
    • MPS-VII
    • その他
  • 治療別の世界のムコ多糖症治療市場
    • 酵素補充療法
    • 幹細胞療法
  • 最終用途別の世界のムコ多糖症治療市場
    • 病院
    • 専門クリニック
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のムコ多糖症治療市場
  • 北米のムコ多糖症治療市場
  • 欧州のムコ多糖症治療市場
  • アジア太平洋ムコ多糖症治療市場
  • その他地域ムコ多糖症治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • タイプ別の世界のムコ多糖症治療市場の成長機会
    • 治療別の世界のムコ多糖症治療市場の成長機会
    • 最終用途別の世界のムコ多糖症治療市場の成長機会
    • 地域別の世界のムコ多糖症治療市場の成長機会
  • 世界のムコ多糖症治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のムコ多糖症治療市場の能力拡大
    • 世界のムコ多糖症治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Take da Pharmaceutical
  • BioMarin Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Abeona Therapeutics
  • Eloxx Pharmaceuticals
  • Esteve
  • Immusoft Corporation
  • Inventiva
  • GC Pharma
目次

Mucopolysaccharidosis Treatment Trends and Forecast

The future of the global mucopolysaccharidosis treatment market looks promising with opportunities in the hospital and specialty clinic markets. The global mucopolysaccharidosis treatment market is expected to reach an estimated $4.2 billion by 2030 with a CAGR of 8.4% from 2024 to 2030. The major drivers for this market are increasing demand for effective treatments, rising prevalence of mucopolysaccharidosis, and rising healthcare spending.

A more than 150-page report is developed to help in your business decisions.

Mucopolysaccharidosis Treatment by Segment

The study includes a forecast for the global mucopolysaccharidosis treatment by type, treatment, end use, and region.

Mucopolysaccharidosis Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • MPS-I
  • MPS-II
  • MPS-IV
  • MPS-VI
  • MPS-VII
  • Others

Mucopolysaccharidosis Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Enzyme Replacement Therapy
  • Stem Cell Therapy

Mucopolysaccharidosis Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Mucopolysaccharidosis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Mucopolysaccharidosis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mucopolysaccharidosis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mucopolysaccharidosis treatment companies profiled in this report include-

  • Take da Pharmaceutical
  • BioMarin Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Abeona Therapeutics
  • Eloxx Pharmaceuticals
  • Esteve
  • Immusoft Corporation
  • Inventiva
  • GC Pharma

Mucopolysaccharidosis Treatment Market Insights

Lucintel forecasts that enzyme replacement therapy will remain the larger segment due to high demand from hospitals and clinics as it help to improve the symptoms and quality of life for MPS patients, and it can also extend their lifespan.

Within this market, hospitals will remain the largest segment over the forecast period due to it has the necessary infrastructure, such as specialized laboratories and equipment, and the necessary expertise like trained healthcare professionals, to provide MPS treatment.

North America will remain the largest segment due to high prevalence of MPS supported by well-established healthcare system and MPS reimbursement policy.

Features of the Global Mucopolysaccharidosis Treatment Market

Market Size Estimates: Mucopolysaccharidosis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mucopolysaccharidosis treatment market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Mucopolysaccharidosis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, end uses, and regions for the mucopolysaccharidosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mucopolysaccharidosis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the mucopolysaccharidosis treatment market size?

Answer: The global mucopolysaccharidosis treatment market is expected to reach an estimated $4.2 billion by 2030.

Q.2 What is the growth forecast for mucopolysaccharidosis treatment market?

Answer: The global mucopolysaccharidosis treatment market is expected to grow with a CAGR of 8.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the mucopolysaccharidosis treatment market?

Answer: The major drivers for this market are increasing demand for effective treatments, rising prevalence of mucopolysaccharidosis and rising healthcare spending.

Q4. What are the major segments for mucopolysaccharidosis treatment market?

Answer: The future of the mucopolysaccharidosis treatment market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key mucopolysaccharidosis treatment market companies?

Answer: Some of the key mucopolysaccharidosis treatment companies are as follows:

  • Take da Pharmaceutical
  • BioMarin Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Abeona Therapeutics
  • Eloxx Pharmaceuticals
  • Esteve
  • Immusoft Corporation
  • Inventiva
  • GC Pharma

Q6. Which mucopolysaccharidosis treatment market segment will be the largest in future?

Answer: Lucintel forecasts that enzyme replacement therapy will remain the larger segment due to high demand from hospitals and clinics as it help to improve the symptoms and quality of life for MPS patients, and it can also extend their lifespan.

Q7. In mucopolysaccharidosis treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of MPS supported by well-established healthcare system and MPS reimbursement policy.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mucopolysaccharidosis treatment market by type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and others), treatment (enzyme replacement therapy and stem cell therapy), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Mucopolysaccharidosis Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Mucopolysaccharidosis Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Mucopolysaccharidosis Treatment Market by Type
    • 3.3.1: MPS-I
    • 3.3.2: MPS-II
    • 3.3.3: MPS-IV
    • 3.3.4: MPS-VI
    • 3.3.5: MPS-VII
    • 3.3.6: Others
  • 3.4: Global Mucopolysaccharidosis Treatment Market by Treatment
    • 3.4.1: Enzyme Replacement Therapy
    • 3.4.2: Stem Cell Therapy
  • 3.5: Global Mucopolysaccharidosis Treatment Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Mucopolysaccharidosis Treatment Market by Region
  • 4.2: North American Mucopolysaccharidosis Treatment Market
    • 4.2.2: North American Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.3: European Mucopolysaccharidosis Treatment Market
    • 4.3.1: European Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.3.2: European Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.4: APAC Mucopolysaccharidosis Treatment Market
    • 4.4.1: APAC Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.4.2: APAC Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.5: ROW Mucopolysaccharidosis Treatment Market
    • 4.5.1: ROW Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
    • 4.5.2: ROW Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Region
  • 6.2: Emerging Trends in the Global Mucopolysaccharidosis Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Mucopolysaccharidosis Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mucopolysaccharidosis Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Take da Pharmaceutical
  • 7.2: BioMarin Pharmaceuticals
  • 7.3: Ultragenyx Pharmaceutical
  • 7.4: Sarepta Therapeutics
  • 7.5: Abeona Therapeutics
  • 7.6: Eloxx Pharmaceuticals
  • 7.7: Esteve
  • 7.8: Immusoft Corporation
  • 7.9: Inventiva
  • 7.10: GC Pharma